Jiangsu Hengrui Medicine Management
Management criteria checks 2/4
Jiangsu Hengrui Medicine's CEO is Hong Bin Dai, appointed in May 2022, has a tenure of 2.75 years. directly owns 0.027% of the company’s shares, worth CN¥76.29M. The average tenure of the management team and the board of directors is 3 years and 4.4 years respectively.
Key information
Hong Bin Dai
Chief executive officer
CN¥3.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.03% |
| Management average tenure | 3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Is Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Trading At A 35% Discount?
Jan 19
Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult
Oct 25Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
Oct 07Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates
Aug 23Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price
Jul 03Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
May 22Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising
Apr 24CEO
Hong Bin Dai (48 yo)
2.8yrs
Tenure
CN¥3,821,700
Compensation
Mr. Hong Bin Dai serves as General Manager of Jiangsu Hengrui Medicine Co., Ltd. since May 2022. He served as Deputy General Manager of Jiangsu Hengrui Medicine Co., Ltd.since April 2013 until May 2022 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 2.8yrs | CN¥3.82m | 0.027% CN¥ 76.3m | |
| Financial Director | 3.3yrs | CN¥2.16m | no data | |
| Deputy GM & Director | no data | CN¥2.35m | 0.030% CN¥ 85.1m | |
| Deputy GM & Director | 12.8yrs | CN¥3.34m | 0.0078% CN¥ 22.2m | |
| Deputy GM & Director | 2yrs | CN¥2.34m | no data | |
| Secretary of the Board of Directors | 9.1yrs | CN¥799.10k | 0.0014% CN¥ 3.9m | |
| Deputy General Manager | 2yrs | CN¥2.47m | 0.023% CN¥ 65.7m | |
| Deputy General Manager | 11.8yrs | CN¥2.05m | 0.0050% CN¥ 14.1m | |
| Deputy General Manager | 4.3yrs | CN¥2.29m | 0.0026% CN¥ 7.4m | |
| Deputy General Manager | no data | CN¥2.14m | 0.0082% CN¥ 23.3m | |
| Deputy General Manager | 2.3yrs | CN¥2.48m | 0.00020% CN¥ 567.8k | |
| Deputy General Manager | 2yrs | CN¥1.09m | 0.0012% CN¥ 3.4m |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Management: 600276's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 5.1yrs | CN¥3.82m | 0.027% CN¥ 76.3m | |
| Deputy GM & Director | 5.1yrs | CN¥2.35m | 0.030% CN¥ 85.1m | |
| Deputy GM & Director | 12.8yrs | CN¥3.34m | 0.0078% CN¥ 22.2m | |
| Deputy GM & Director | 2yrs | CN¥2.34m | no data | |
| Chairman of the Board of Directors | 22.1yrs | CN¥1.62m | no data | |
| Employee Representative Member of the Supervisory Committee | 11.8yrs | CN¥120.00k | no data | |
| Chairman of the Supervisory Board | 2yrs | CN¥2.93m | 0.020% CN¥ 57.0m | |
| Independent Director | 2yrs | CN¥100.00k | no data | |
| Independent Director | 2yrs | CN¥100.00k | no data | |
| Director | 5.1yrs | no data | no data | |
| Independent Director | 3.8yrs | no data | no data | |
| Employee Representative Supervisor | 2.6yrs | no data | no data |
4.4yrs
Average Tenure
53yo
Average Age
Experienced Board: 600276's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 07:10 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangsu Hengrui Medicine Co., Ltd. is covered by 62 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Changming He | BOCI Research Ltd. |
| Bo Li | BofA Global Research |